Day One Biopharmaceuticals’ Post

✅In the structure of PTK7 ADC MTX-13, the MC-VC component is standard. Still, it includes a T-moiety designed to reduce the hydrophobicity of exatecan and act as a self-immolative group. This structure was co-developed by Multitude Therapeutics and HySlink Therapeutics. MTX-13 aims to improve upon the discontinued Cofetuzumab Pelidotin, initially developed by Pfizer and AbbVie. 💡While it is unclear which indications Day One Biopharmaceuticals will pursue with MTX-13, preclinical studies suggest its potential in SCLC and various squamous cell carcinomas. Given Day One’s innovative clinical development strategy demonstrated with tovorafenib, unexpected indications might also be explored. 💡SCLC has shown promising data with ADCs targeting B7-H3 and SEZ6, but there is limited information on target expression and efficacy across the four subtypes classified by transcription factor expression patterns. PTK7 demonstrated consistent expression across all subtypes in both PDX samples and human SCLC samples, compared to B7-H3 and DLL3. MTX-13 exhibited consistent tumor suppression in SCLC-A subtype PDX models, outperforming other drugs. Ref: 1. MTX-13, a Novel PTK7-Directed Antibody–Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors https://lnkd.in/gSbWj828 2. Antibody–Exatecan Conjugates with a Novel Self-immolative Moiety Overcome Resistance in Colon and Lung Cancer https://lnkd.in/gNTn5JaZ

"However, the problem with recurrent glioblastoma is that survival is quite short. And current therapies have not changed that." Join us on June 26th, Wednesday, 1PM Eastern for Lantern Pharma Webinar Wednesdays - STAR-001 in Multiple Brain and CNS Cancers, featuring Dr. Marc Chamberlain, CMO of Starlight Therapeutics. In this webinar, Dr. Chamberlain talks about current challenges and possible breakthroughs in treating #Glioblastoma (#GBM). Glioblastoma is a fast-growing and aggressive brain tumor that accounts for 50% of all primary malignant brain tumors. GBM is one of the Starlight's main focuses, with an ongoing Phase 1a clinical trial and Phase 1b trial planned for the future. Register now to join the webinar to learn more about Starlight's focuses, how they are working towards finding better treatment options for patients with this awful disease. https://bit.ly/4bZEkg7

While multiple new treatment options for Ovarian Cancer have been introduced in recent years, recurrence risk remains high, and physicians have had to rely on imperfect biomarkers to determine who is likely to benefit from these more intensive regimens, assess response to therapy, and monitor for recurrence. Circulating tumor DNA (ctDNA), as measured by the Signatera™ assay, has emerged as a highly sensitive biomarker to identify patient populations who are at high risk of relapse and may benefit from additional treatment. Our expert speakers will discuss: • The latest ctDNA data from recent publications and SGO 2024 • Opportunities to improve improve patient care in gynecologic cancers • Future directions and implications for drug development and clinical trial design Register to attend or receive a link to watch on demand: https://lnkd.in/gZ9-stEM https://lnkd.in/gEh_m5Sg

Read Dr. Joshua Richter’s article on measurable residual disease (MRD) testing in the community oncology setting: https://clonoseq.co/nu9. This article covers how to use highly sensitive MRD assessment methods, such as clonoSEQ—which can detect MRD at a threshold of 10-6, given sufficient sample input, to gain critical insights to help guide your approach for lymphoid malignancy patients. FDA-cleared to measure MRD in MM, CLL, & ALL; CLIA-validated in other lymphoid cancers. Info on sample types & test limitations: https://rb.gy/8tju9y

OS Therapies remains dedicated to developing new treatments for osteosarcoma, bringing hope to those battling this aggressive bone cancer. Our Phase 2b OST-HER2 study in osteosarcoma has received FDA designations: Rare Pediatric Disease Designation (RPDD), Orphan Drug Designation (ODD), and Fast Track Designation (FTD). OST-HER2’s strong safety profile supports its potential to become a practical adjuvant therapy to delay or prevent subsequent recurrences and improve overall survival in the very difficult challenge of recurrent osteosarcoma. The trial is fully enrolled with final data expected in Q4-24. https://bit.ly/3A5ScHW  #SarcomaAwareness #Osteosarcoma #CancerResearch #HopeForCures $OSTX

Exploring the feasibility, safety and early survival outcomes of HIPEC in addition to interval CRS for two unaddressed sub-groups ⏩ stage IV disease ⏩ >4 cycles of NACT Open access https://lnkd.in/djTzbSF8 Encouraging PFS for these 'difficult' and unaddressed subgroups European Society of Surgical Oncology (ESSO) American Society of Clinical Oncology (ASCO) #HIPEC #OVARIANCANCER #INTERVALCYTOREDUCTIVESURGERY #INTERVALDEBULKING

Today is #GlioblastomaAwarenessDay. Three years ago, I had no idea what #Glioblastoma was. Not until my mom was diagnosed with #GBM in 2021 and lost her battle after 10 short months. GBM is the most common of all primary malignant brain tumors, yet remains fairly unresearched with only 4 FDA approved drugs to treat it. GBM is one of the most complex, deadly, and treatment-resistant cancers. Today, I ask that we spread awareness about GBM and inspire others to take action to ensure better treatments and cures for GBM patients. #GBMDay Learn more about how you can get involved here: https://lnkd.in/g7YP_xrP

In FORT-2, rogaratinib and atezolizumab showed tolerable safety with a high objective response rate (54%) in patients with FGFR mRNA-overexpressing urothelial cancer. Patient selection by mRNA FGFR3 overexpression may expand FGFR inhibitor benefit. https://ja.ma/3MSi9xu

The IMbrave150 study offers key insights into treating advanced hepatocellular carcinoma with atezolizumab and bevacizumab. Patients with durable responses, including significant tumor reduction (PR) or stable disease (SD), had notably long survival. Interestingly, many tumors that appeared on imaging still showed no viable cancer cells upon resection (PCR - Pathologic Complete Response rates). This underscores the need to improve imaging techniques to better evaluate true treatment efficacy. Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus Bevacizumab Journal of Clinical Oncology, August 28, 2024 https://lnkd.in/dUN2_m2v

Risk Factors for Late Recurrence and Post-Relapse Survival in ER-Positive, HER2-Negative Breast Cancer After 5 Years of Endocrine Therapy The Breast TAKE-HOME MESSAGE This retrospective study involving 892 patients with ER+/HER2− breast cancer without distant metastasis after 5 years of adjuvant endocrine therapy showed that the risk factors for late distant recurrence were lymph node involvement, large tumor size, high tumor grade, and locoregional recurrence. Patients at high risk for late recurrence benefited from extended endocrine therapy. The results suggest that patients with longer distant disease–free survival (≥7 years) can be expected to have a better response to endocrine therapy and a longer positive prognosis. Patients with a progression-free survival duration of less than 12 months after first-line endocrine treatment may have endocrine resistance. Therefore, longer distant disease–free survival and response to first-line treatment may affect post-relapse survival after late recurrence.